Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Istituto Scientifico H. San Raffaele
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00989690
First received: October 2, 2009
Last updated: August 9, 2013
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying the proteins expressed in samples of blood and tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This randomized phase III trial is studying blood and tissue samples in predicting response to second-line therapy using erlotinib hydrochloride or chemotherapy in patients with advanced non-small cell lung cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Lung Cancer |
Drug: docetaxel Drug: erlotinib hydrochloride Drug: pemetrexed disodium Genetic: fluorescence in situ hybridization Genetic: mutation analysis Genetic: proteomic profiling Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry Procedure: breath test |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer |
Resource links provided by NLM:
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Overall survival [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Progression-free survival [ Designated as safety issue: No ]
- Overall response rate according to RECIST criteria [ Designated as safety issue: No ]
| Estimated Enrollment: | 275 |
| Study Start Date: | February 2008 |
OBJECTIVES:
- To evaluate the predictive value of proteomic profiling on the effect of second-line therapy with erlotinib hydrochloride vs standard chemotherapy (pemetrexed disodium or docetaxel) in patients with advanced non-small cell lung cancer.
- To assess the role of other known tissue-based predictive markers (e.g., EGFR-gene copy number, EGFR-protein expression, pAkt, pMAPK, EGFR mutations, EMT markers, and k-Ras mutation).
OUTLINE: This is a multicenter study. Patients are stratified according to smoking status, performance status, proteomic profile, and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive standard chemotherapy with pemetrexed disodium, docetaxel, or another standard drug.
- Arm II: Patients receive standard non-chemotherapy treatment with erlotinib hydrochloride.
Serum is collected after failure of first-line therapy for proteomic analysis by matrix-associated laser desorption/ionization-time of flight. Tissue and blood samples are collected periodically for analysis including EGFR based on IHC and FISH, EGFR and k-Ras mutations, pAkt, pMAPK by IHC, and EMT markers based on IHC and breath condensate protein profile.
After completion of study treatment, patients are followed every 2 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
-
Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- Advanced NSCLC (stage IIIB or IV)
- Measurable disease
- Underwent previous treatment with 1 non-tyrosine kinase inhibitor as first-line therapy for advanced NSCLC
- No clinical evidence of uncontrolled brain metastases
PATIENT CHARACTERISTICS:
- Caucasian
- ECOG performance status 0-2
- Absolute granulocyte count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 2.5 times ULN in patients with known liver metastases)
- ALT or AST ≤ 3 times ULN (≤ 5 times ULN in patients with known liver metastases)
- Creatinine clearance ≥ 50 mL/min
- Not pregnant or nursing
- Able to comply with planned study procedures
- No multiple severe diseases that can compromise safety (cardiac and renal failure, peripheral neuropathy)
- No other malignancy (except for basal cell skin carcinoma) or pre-neoplastic condition requiring chemotherapeutic treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 3 weeks since prior surgery or radiotherapy
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00989690
Please refer to this study by its ClinicalTrials.gov identifier: NCT00989690
Locations
| Italy | |
| Istituto Scientifico H. San Raffaele | Recruiting |
| Milan, Italy, 20132 | |
| Contact: Vanesa Gregor, MD 39-02-2643-7623 | |
Sponsors and Collaborators
Istituto Scientifico H. San Raffaele
Investigators
| Principal Investigator: | Vanesa Gregor, MD | Istituto Scientifico H. San Raffaele |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00989690 History of Changes |
| Other Study ID Numbers: | SRSI-HSRL-02-2007, CDR0000652115, 2007-006299-13, EU-20975 |
| Study First Received: | October 2, 2009 |
| Last Updated: | August 9, 2013 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
recurrent non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Neoplasms Neoplasms by Site Respiratory Tract Diseases |
Respiratory Tract Neoplasms Thoracic Neoplasms Erlotinib Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protein Kinase Inhibitors |
ClinicalTrials.gov processed this record on February 27, 2015